Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to 0.29.

  • Rhythm Pharmaceuticals' Equity Ratio rose 85179.56% to 0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.29, marking a year-over-year increase of 85179.56%. This contributed to the annual value of 0.06 for FY2024, which is 8914.25% down from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Equity Ratio of 0.29 as of Q3 2025, which was up 85179.56% from 0.03 recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Equity Ratio registered a high of 0.91 during Q3 2021, and its lowest value of 0.03 during Q2 2025.
  • Moreover, its 5-year median value for Equity Ratio was 0.59 (2023), whereas its average is 0.5.
  • Within the past 5 years, the most significant YoY rise in Rhythm Pharmaceuticals' Equity Ratio was 85179.56% (2025), while the steepest drop was 13100.71% (2025).
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Equity Ratio stood at 0.86 in 2021, then dropped by 19.88% to 0.69 in 2022, then dropped by 26.16% to 0.51 in 2023, then tumbled by 89.14% to 0.06 in 2024, then surged by 430.03% to 0.29 in 2025.
  • Its Equity Ratio was 0.29 in Q3 2025, compared to 0.03 in Q2 2025 and 0.05 in Q1 2025.